Effects of Beraprost Sodium on subjective symptoms in diabetic patients with peripheral arterial disease

Hang Seob Yoon, Woo Jin Choi, Il Hoon Sung, Ho Seong Lee, Hyung Jin Chung, Jin Woo Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. Methods: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. Beraprost (40 μg) was administered orally 3 times daily (120 μg/day) for 12 weeks. We developed a new disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written questionnaire before treatment and after 12 weeks of therapy. Results: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, stabbing, and paresthesias) in the lower extremities at 12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse events considered to be drug-related were observed in 4 patients (4.3%), all of which were mild and resolved with discontinuation of the medication. Conclusions: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalClinics in Orthopedic Surgery
Volume5
Issue number2
DOIs
Publication statusPublished - 2013 Jun

Fingerprint

beraprost
Peripheral Arterial Disease
Paresthesia
Lower Extremity
Edema
Leg
Therapeutics
Pain
Symptom Assessment
Multicenter Studies
Diabetes Mellitus
Cohort Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Yoon, Hang Seob ; Choi, Woo Jin ; Sung, Il Hoon ; Lee, Ho Seong ; Chung, Hyung Jin ; Lee, Jin Woo. / Effects of Beraprost Sodium on subjective symptoms in diabetic patients with peripheral arterial disease. In: Clinics in Orthopedic Surgery. 2013 ; Vol. 5, No. 2. pp. 145-151.
@article{e489f476011a4cac91c02715875294bf,
title = "Effects of Beraprost Sodium on subjective symptoms in diabetic patients with peripheral arterial disease",
abstract = "Background: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. Methods: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. Beraprost (40 μg) was administered orally 3 times daily (120 μg/day) for 12 weeks. We developed a new disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written questionnaire before treatment and after 12 weeks of therapy. Results: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, stabbing, and paresthesias) in the lower extremities at 12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse events considered to be drug-related were observed in 4 patients (4.3{\%}), all of which were mild and resolved with discontinuation of the medication. Conclusions: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease.",
author = "Yoon, {Hang Seob} and Choi, {Woo Jin} and Sung, {Il Hoon} and Lee, {Ho Seong} and Chung, {Hyung Jin} and Lee, {Jin Woo}",
year = "2013",
month = "6",
doi = "10.4055/cios.2013.5.2.145",
language = "English",
volume = "5",
pages = "145--151",
journal = "Clinics in Orthopedic Surgery",
issn = "2005-291X",
publisher = "Korean Orthopaedic Association",
number = "2",

}

Effects of Beraprost Sodium on subjective symptoms in diabetic patients with peripheral arterial disease. / Yoon, Hang Seob; Choi, Woo Jin; Sung, Il Hoon; Lee, Ho Seong; Chung, Hyung Jin; Lee, Jin Woo.

In: Clinics in Orthopedic Surgery, Vol. 5, No. 2, 06.2013, p. 145-151.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of Beraprost Sodium on subjective symptoms in diabetic patients with peripheral arterial disease

AU - Yoon, Hang Seob

AU - Choi, Woo Jin

AU - Sung, Il Hoon

AU - Lee, Ho Seong

AU - Chung, Hyung Jin

AU - Lee, Jin Woo

PY - 2013/6

Y1 - 2013/6

N2 - Background: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. Methods: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. Beraprost (40 μg) was administered orally 3 times daily (120 μg/day) for 12 weeks. We developed a new disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written questionnaire before treatment and after 12 weeks of therapy. Results: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, stabbing, and paresthesias) in the lower extremities at 12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse events considered to be drug-related were observed in 4 patients (4.3%), all of which were mild and resolved with discontinuation of the medication. Conclusions: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease.

AB - Background: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. Methods: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. Beraprost (40 μg) was administered orally 3 times daily (120 μg/day) for 12 weeks. We developed a new disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written questionnaire before treatment and after 12 weeks of therapy. Results: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, stabbing, and paresthesias) in the lower extremities at 12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse events considered to be drug-related were observed in 4 patients (4.3%), all of which were mild and resolved with discontinuation of the medication. Conclusions: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease.

UR - http://www.scopus.com/inward/record.url?scp=84878156565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878156565&partnerID=8YFLogxK

U2 - 10.4055/cios.2013.5.2.145

DO - 10.4055/cios.2013.5.2.145

M3 - Article

C2 - 23730480

AN - SCOPUS:84878156565

VL - 5

SP - 145

EP - 151

JO - Clinics in Orthopedic Surgery

JF - Clinics in Orthopedic Surgery

SN - 2005-291X

IS - 2

ER -